What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Topical AD-303A applied to the scalp according to the study protocol.”In the company’s words, NCT07490327 on ClinicalTrials.gov
- Tested for
- Androgenetic Alopecia
- Main trialPhase 1/2
- “This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.”In the company’s words, NCT07490327 on ClinicalTrials.gov
Other drugs for Androgenetic Alopecia
- RitlecitinibPfizer · Phase 3
- VDPHL01Veradermics, Inc. · Phase 3
- OMA102EMS · Phase 3
- DA-001Applied Biology, Inc. · Phase 2/3
- DeuruxolitinibSun Pharma · Phase 3
- CKD-843Chong Kun Dang Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | Sep 2026 | Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026